PortalPublikationenA novel risk-scoring system conducing to chemotherapy decisi...

A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy

Standard

A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. / Li, Yuqiang; Tian, Mengxiang; Zhou, Yuan; Tan, Fengbo; Liu, Wenxue; Zhao, Lilan; Perez, Daniel; Song, Xiangping; Wang, Dan; Nitschke, Christine; Pei, Qian; Güngör, Cenap.

in: J CANCER, Jahrgang 12, Nr. 14, 2021, S. 4433-4442.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Li, Y, Tian, M, Zhou, Y, Tan, F, Liu, W, Zhao, L, Perez, D, Song, X, Wang, D, Nitschke, C, Pei, Q & Güngör, C 2021, 'A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy', J CANCER, Jg. 12, Nr. 14, S. 4433-4442. https://doi.org/10.7150/jca.57768

APA

Li, Y., Tian, M., Zhou, Y., Tan, F., Liu, W., Zhao, L., Perez, D., Song, X., Wang, D., Nitschke, C., Pei, Q., & Güngör, C. (2021). A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. J CANCER, 12(14), 4433-4442. https://doi.org/10.7150/jca.57768

Vancouver

Li Y, Tian M, Zhou Y, Tan F, Liu W, Zhao L et al. A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy. J CANCER. 2021;12(14):4433-4442. https://doi.org/10.7150/jca.57768

Bibtex

@article{bb6740fed15540918c20fa7200e3db1d,
title = "A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy",
abstract = "Background: Chemotherapy is suggested to use in all stages of pancreatic cancer. Is it reasonable to recommend chemotherapy for all PDAC patients? It is necessary to distinguish low-risk PDAC patients underwent pancreatectomy, who may not lose survival time due to missed chemotherapy and not need to endure pain, nausea, tiredness, drowsiness, and breath shortness caused by chemotherapy. Methods: Nomograms were constructed with basis from the multivariate Cox regression analysis. X-tile software was utilized to perform risk stratification. Survival curves were used to display the effect of chemotherapy in different risk-stratification. Results: All of the significant variables were used to create the nomograms for overall survival (OS). The total risk score of each patient was calculated by summing the scores related to each variable. X-tile software was utilized to classify patients into high-risk (score >283), median-risk (197",
author = "Yuqiang Li and Mengxiang Tian and Yuan Zhou and Fengbo Tan and Wenxue Liu and Lilan Zhao and Daniel Perez and Xiangping Song and Dan Wang and Christine Nitschke and Qian Pei and Cenap G{\"u}ng{\"o}r",
note = "{\textcopyright} The author(s).",
year = "2021",
doi = "10.7150/jca.57768",
language = "English",
volume = "12",
pages = "4433--4442",
journal = "J CANCER",
issn = "1837-9664",
publisher = "IVYSPRING INT PUBL ",
number = "14",

}

RIS

TY - JOUR

T1 - A novel risk-scoring system conducing to chemotherapy decision for patients with pancreatic ductal adenocarcinoma after pancreatectomy

AU - Li, Yuqiang

AU - Tian, Mengxiang

AU - Zhou, Yuan

AU - Tan, Fengbo

AU - Liu, Wenxue

AU - Zhao, Lilan

AU - Perez, Daniel

AU - Song, Xiangping

AU - Wang, Dan

AU - Nitschke, Christine

AU - Pei, Qian

AU - Güngör, Cenap

N1 - © The author(s).

PY - 2021

Y1 - 2021

N2 - Background: Chemotherapy is suggested to use in all stages of pancreatic cancer. Is it reasonable to recommend chemotherapy for all PDAC patients? It is necessary to distinguish low-risk PDAC patients underwent pancreatectomy, who may not lose survival time due to missed chemotherapy and not need to endure pain, nausea, tiredness, drowsiness, and breath shortness caused by chemotherapy. Methods: Nomograms were constructed with basis from the multivariate Cox regression analysis. X-tile software was utilized to perform risk stratification. Survival curves were used to display the effect of chemotherapy in different risk-stratification. Results: All of the significant variables were used to create the nomograms for overall survival (OS). The total risk score of each patient was calculated by summing the scores related to each variable. X-tile software was utilized to classify patients into high-risk (score >283), median-risk (197

AB - Background: Chemotherapy is suggested to use in all stages of pancreatic cancer. Is it reasonable to recommend chemotherapy for all PDAC patients? It is necessary to distinguish low-risk PDAC patients underwent pancreatectomy, who may not lose survival time due to missed chemotherapy and not need to endure pain, nausea, tiredness, drowsiness, and breath shortness caused by chemotherapy. Methods: Nomograms were constructed with basis from the multivariate Cox regression analysis. X-tile software was utilized to perform risk stratification. Survival curves were used to display the effect of chemotherapy in different risk-stratification. Results: All of the significant variables were used to create the nomograms for overall survival (OS). The total risk score of each patient was calculated by summing the scores related to each variable. X-tile software was utilized to classify patients into high-risk (score >283), median-risk (197

U2 - 10.7150/jca.57768

DO - 10.7150/jca.57768

M3 - SCORING: Journal article

C2 - 34093844

VL - 12

SP - 4433

EP - 4442

JO - J CANCER

JF - J CANCER

SN - 1837-9664

IS - 14

ER -